Eiger Biopharmaceuticals Inc (EIGR) Down 5.13% in Premarket Trading

Eiger Biopharmaceuticals Inc (EIGR) has fallen Friday morning, with the stock falling -5.13% in pre-market trading to 1.11. EIGR's short-term technical score of 0 indicates that the stock has traded less bullishly over the last month than 100% of stocks on the market. In the Biotechnology industry, which ranks 124 out of 146 industries, EIGR ranks higher than 1% of stocks. Eiger Biopharmaceuticals Inc has fallen 71.04% over the past month, closing at $4.45 on November 11. During this period of time, the stock fell as low as $1.17 and as high as $4.69. EIGR has an average analyst recommendation of Strong Buy. The company has an average price target of $32.00.

EIGR has an Overall Score of 24. Find out what this means to you and get the rest of the rankings on EIGR!

See Full EIGR Report

Eiger Biopharmaceuticals Inc has a Long-Term Technical rank of 1. This means that trading over the last 200 trading days has placed the company in the lower half of stocks with 99% of the market scoring higher. In the Biotechnology industry which is number 130 by this metric, EIGR ranks better than 130% of stocks.

Important Dates for Investors in EIGR:

-Eiger Biopharmaceuticals Inc is set to release earnings on 2/1/2023. Over the last 12 months, the company has reported EPS of $-2.41. -We do not have a set dividend date for Eiger Biopharmaceuticals Inc at this time. Click Here To Get The Full Report on Eiger Biopharmaceuticals Inc (EIGR)